Bioline RX Ltd Sponsored ADR ( (BLRX) ) has provided an update.
On March 31, 2025, BioLineRx Ltd. reported its 2024 financial results, highlighting significant strategic shifts and financial achievements. The company executed a licensing agreement with Ayrmid Pharma Ltd. for APHEXDA, receiving $10 million upfront and potential milestones up to $87 million, alongside high double-digit royalties. This move, along with cost reductions and recent financings, has extended BioLineRx’s cash runway through the second half of 2026. The company also reported a 502.1% increase in revenues for 2024, driven by licensing payments and product sales, and a significant reduction in operating expenses. These developments position BioLineRx to focus on in-licensing additional assets and advancing its oncology and rare disease therapies, ensuring sustained value creation for shareholders.
More about Bioline RX Ltd Sponsored ADR
BioLineRx Ltd. is a development stage biopharmaceutical company based in Israel, focusing on creating life-changing therapies in the fields of oncology and rare diseases.
YTD Price Performance: -64.37%
Average Trading Volume: 228,419
Technical Sentiment Signal: Buy
Current Market Cap: $11.49M
For an in-depth examination of BLRX stock, go to TipRanks’ Stock Analysis page.